MRK Merck & Company Inc
Company Analysis
Latest News
Merck Reportedly Among Bidders for Cancer Diagnostics Firm Personalis
Cancer diagnostics company Personalis (PSNL) explores a sale. The company received takeover interest from Merck (MRK) and at least two other bidders....
🟢 Merck is trading 3.1% up today after FDA approval of oral cholesterol drug Lipfendra
Merck is trading 3.1% up at $131.54 after winning FDA approval for Lipfendra, the first once-daily oral PCSK9 inhibitor for lowering LDL cholesterol in...
Merck Wins FDA Approval for Lipfendra, First Oral Cholesterol-Lowering Pill
The U.S. Food and Drug Administration approved Merck’s Lipfendra (enlicitide) for the treatment of hypercholesterolemia. This once-daily pill represents the...
🟢 Merck is trading 3.2% up today as UnitedHealth earnings lift healthcare sector
Merck is trading 3.2% up at $127.62 as a rally in healthcare stocks, sparked by strong UnitedHealth results, lifts the broader sector. • The XLV healthcare...
Merck to Unveil Phase 3 Data on Once-Weekly HIV Regimen at AIDS 2026
Merck will present new data from its HIV treatment and prevention pipeline. The company will present this data at the 26th International AIDS Conference (AIDS...
Merck Keytruda Beats Chemotherapy, Offering New Option for Endometrial Cancer
Merck’s Phase 3 KEYNOTE-C93 trial met its primary endpoint for the treatment of endometrial cancer. Keytruda monotherapy significantly improved...
Merck Secures EU Approval for Erbitux, Driving Wall Street Price Hikes
The European Commission approved Merck’s Erbitux on July 14, 2026. This regulatory green light covers Erbitux in combination with encorafenib and FOLFOX for...
Merck Secures FDA Breakthrough Status for Lupus Drug, Price Target Raised
The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to Merck’s enpatoran. This investigational oral TLR7/8 inhibitor treats...
Merck Hits 52-Week High, Boosted by Lung Cancer Drug Pipeline
Merck & Co. shares reached a new 12-month high of $130.29 on Wednesday. Bank of America raised its price target for the stock to $141 from $130. The firm also...
Merck faces US probe over China trials, citing military and IP risks
A bipartisan U.S. House committee launched a national security investigation into Merck & Co. regarding its clinical drug trials in China. The House Select...
Merck Wins FDA Approval for Keytruda-Trodelvy Combo, Cutting Cancer Risk 35%
The FDA approved Merck’s KEYTRUDA in combination with Gilead’s Trodelvy for advanced triple-negative breast cancer (TNBC). This approval applies to adult...
🟢 MRK is trading 3.2% up today on EU approval for Keytruda bladder cancer combo
MRK is trading 3.2% up at $124.40 after winning a key European regulatory approval for its oncology portfolio. • The European Commission cleared the...
Merck Secures EU Approval for Keytruda Combo, First-of-Its-Kind Bladder Cancer Treatment
The European Commission approved Merck’s anti-PD-1 therapy, Keytruda, in combination with Padcev. The regimen treats adult patients with resectable...
Merck Tulisokibart Hits Phase 3 Goal, First-in-Class Success for Ulcerative Colitis
Merck reported positive topline results from the Phase 3 ATLAS-UC induction-only study for tulisokibart. This investigational treatment targets patients with...
🔴 Merck & Company Inc is trading 3.1% down today despite expanded CAPVAXIVE FDA approval
Merck & Company Inc is trading 3.1% down at $111.83 despite announcing expanded FDA approval for its CAPVAXIVE pneumococcal vaccine in high-risk children and...
Merck Expands CAPVAXIVE FDA Approval to High-Risk Children and Teens
Merck received FDA approval for the expanded use of its pneumococcal vaccine, CAPVAXIVE. The new indication covers children and adolescents aged 2 through 17...
Merck Shares Fall 3%, Medicare Rule Targets Keytruda Patent Loophole
Merck & Co. (MRK) shares fell over 3% on June 15. The Centers for Medicare & Medicaid Services (CMS) proposed a permanent framework for negotiating drug...
Merck Wins FDA Approval for Kidney Cancer Combo, Slashing Recurrence Risk
The FDA approved Merck’s Welireg (belzutifan) in combination with Keytruda (pembrolizumab) for adult patients with renal cell carcinoma (RCC). The treatment...
Merck and Gilead Scrap Keytruda Combination Trial, Citing Efficacy Shortfall
Merck and Gilead Sciences discontinued the Phase 3 KEYNOTE-D46/EVOKE-03 study. The trial evaluated a combination of Keytruda and Trodelvy for metastatic...
Merck and Gilead Report Success for First Once-Weekly Oral HIV Pill
Merck and Gilead Sciences announced positive topline results from two Phase 3 trials, ISLEND-1 and ISLEND-2. The studies evaluated a once-weekly oral...